DCM
SIOX

DAFNA Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

DAFNA Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-171,083
Closed -$790K – 88
2020
Q3 		$790K Sell
171,083
-834,308
-83% -$2.75M 0.26% 60
2020
Q2 		$2.83M Sell
1,005,391
-16,175
-2% -$51.9K 0.82% 34
2020
Q1 		$2.49M Buy
+1,021,566
New +$3.69M 1.04% 28

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $227M AUM 402.2% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

DAFNA Capital Management's SIOX Position: Q4 2020 in Review

DAFNA Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2020, closing a stake of 171,083 shares — an estimated $790K sold.

DAFNA Capital Management first reported a position in SIOX in Q1 2020 and held it in 3 quarters. The position peaked at $2.83M in Q2 2020. 62 funds tracked by Wall St. Rank hold SIOX as of Q4 2020.

  • DAFNA Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 171,083 Sio Gene Therapies Inc. Common Stock shares in Q4 2020, an estimated $790K.
  • DAFNA Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • DAFNA Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $2.83M in Q2 2020.
  • 62 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2020.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.